Rubix LS, a minority-led life science research firm focusing on solutions to support minorities within clinical trials, announced today that it had completed a $1.25 million Seed round of financing. With the financing round being secured by many private and angel investors, the investment capitalizes on the further momentum for the virtual clinical trial platform, StarSense, and the intimate engagement with minority patients for continued care for early-stage research. Harmonizing on the events during the COVID-19 pandemic, StarSense made further advances globally to support underrepresented groups to be included in infectious disease clinical trial research programs. Furthering from inclusion, the platform has led to a 38% increase in therapeutic benefits for therapies that were otherwise unknown to support and treat specific conditions.
“We’re ensuring that we don’t let the pandemic and any further instances of innovation disregard the underrepresented communities from accessing therapies for conditions and start building trust among the communities at large.” – Reginald Swift, Founder & CEO of Rubix LS
The Seed financing builds on an exceptional year for Rubix LS which saw a rapidly growing roster of clients, expansion of its internal team, and key market momentum in the white-hot areas of health inequities towards the underrepresented patient populations that has stemmed from the race for a vaccine for COVID-19.
About Rubix LS
Rubix LS, founded in 2016, is a culturally-centric life science research firm that is building data, products, processes, and programs to wholly support the clinical research continuum that includes minority data sets in every phase of the life science development ecosystem. Enabling its the use of virtual clinical trials, it is bridging the scientific and operational expertise to design custom made solutions that enhance minority patient attention, recruitment, engagement, support, and education so that the life science industry can make better products for everyone.